Pulmonary Outcome at 1 Year Corrected Age in Premature Infants Treated at Birth With Recombinant Human CuZn Superoxide Dismutase
Authors:
- Jonathan M. DavisJDJonathan M. Davis
- for the North American Recombinant Human CuZnSOD Study GroupFGfor the North American Recombinant Human CuZnSOD Study Group
- 1 March 2003
- journal article
- clinical trial
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 111 (3) , 469-476
Abstract
Objective. To examine whether treatment of premature infants with intratracheal recombinant human CuZn superoxide dismutase (r-h CuZnSOD) reduces bronchopulmonary dysplasia and improves pulmonary outcome at 1 year corrected age. Design. Three hundred two premature infants (600–1200 g birth weight) treated with exogenous surfactant at birth for respiratory distress syndrome were randomized to receive either intratracheal r-h CuZnSOD (5 mg/kg in 2 mL/kg saline) or placebo every 48 hours (as long as intubation was required) for up to 1 month of age. Short-term, as well as longer-term pulmonary outcome was assessed. Results. There were no differences between groups in the incidence of death or the development of bronchopulmonary dysplasia (oxygen requirement with an Edwards chest radiograph score of ≥3) at 28 days of life or 36 weeks’ postmenstrual age. r-h CuZnSOD was well-tolerated and not associated with significant increases in any adverse event. At a median of 1 year corrected age, health assessments and physical examinations were performed on 209 (80%) surviving infants, with complete data available on 189 infants. Thirty-seven percent of placebo-treated infants had repeated episodes of wheezing or other respiratory illness severe enough to require treatment with asthma medications such as bronchodilators and/or corticosteroids compared with 24% of r-h CuZnSOD-treated infants, a 36% reduction. In infants Conclusions. These data indicate that treatment at birth with r-h CuZnSOD may reduce early pulmonary injury, resulting in improved clinical status when measured at 1 year corrected age. r-h CuZnSOD appears to be a safe and effective therapy that improves pulmonary outcome in high-risk premature infants.Keywords
This publication has 34 references indexed in Scilit:
- Effects of Exogenous Surfactant and Recombinant Human Copper-Zinc Superoxide Dismutase on Oxygen-Dependent Antimicrobial DefensesNeonatology, 2002
- Home oxygen status and rehospitalisation and primary care requirements of infants with chronic lung diseaseArchives of Disease in Childhood, 2002
- Prevalence of nosocomial infections in neonatal intensive care unit patients: Results from the first national point-prevalence surveyThe Journal of Pediatrics, 2001
- Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP), A Randomized, Controlled Trial. I: Primary OutcomesPediatrics, 2000
- Evaluation of criteria for chronic lung disease in surviving very low birth weight infantsThe Journal of Pediatrics, 1998
- Respiratory morbidity in preschool children born prematurely. Relationship to adverse neonatal eventsActa Paediatrica, 1996
- Early protein oxidation in the neonatal lung is related to development of chronic lung diseaseActa Paediatrica, 1995
- Transgenic mice with expression of elevated levels of copper-zinc superoxide dismutase in the lungs are resistant to pulmonary oxygen toxicity.Journal of Clinical Investigation, 1991
- Correlation of free oxygen radical-induced lipid peroxidation with outcome in very low birth weight infantsThe Journal of Pediatrics, 1990
- An Improper Use of Statistical Significance Testing in Studying CovariablesInternational Journal of Epidemiology, 1978